Trevi Therapeutics (TRVL) Prices 5.5M Share IPO at $10/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Trevi Therapeutics (TRVI) IPO Opens Modestly Lower
May 7, 2019 12:57 PM EDTToday's IPO for Trevi Therapeutics (NASDAQ: TRVI) opened for trading at $9.50 after pricing 5,500,000 shares at $10.
The offering was led by SVB Leerink, Stifel, BMO, and Needham & Company.
About the Company:
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically... More
